Infection and Vaccine Induced Spike Antibody Responses Against SARS-CoV-2 Variants of Concern in COVID-19-Naïve Children and Adults.

Autor:	Pillay A; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Yeola A; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Tea F; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Denkova M; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Houston S; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Burrell R; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Merheb V; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Lee FXZ; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Lopez JA; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Moran L; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; National Center for Immunisation Research and Surveillance, the Sydney Children's Hospitals Network, Sydney, New South Wales, Australia., Jadhav A; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; National Center for Immunisation Research and Surveillance, the Sydney Children's Hospitals Network, Sydney, New South Wales, Australia., Sterling K; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; National Center for Immunisation Research and Surveillance, the Sydney Children's Hospitals Network, Sydney, New South Wales, Australia., Lai CL; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Vitagliano TL; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Aggarwal A; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia., Catchpoole D; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia., Wood N; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; National Center for Immunisation Research and Surveillance, the Sydney Children's Hospitals Network, Sydney, New South Wales, Australia., Phan TG; Garvan Institute of Medical Research, Sydney, New South Wales, Australia.; St Vincent's Healthcare Clinical Campus, School of Clinical Medicine, Faculty of Medicine and Health, The University of New South Wales, Sydney, New South Wales, Australia., Nanan R; Charles Perkins Center and Sydney Medical School Nepean, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Hsu P; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; Department of Allergy and Immunology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia., Turville SG; The Kirby Institute, The University of New South Wales, Sydney, New South Wales, Australia., Britton PN; Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia.; Sydney Institute for Infectious Disease, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Brilot F; Brain Autoimmunity Group, Kids Neuroscience Centre, Kids Research at the Children's Hospital at Westmead, Sydney, New South Wales, Australia. Fabienne.brilot@sydney.edu.au.; School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Fabienne.brilot@sydney.edu.au.; Sydney Institute for Infectious Disease, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia. Fabienne.brilot@sydney.edu.au.; Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia. Fabienne.brilot@sydney.edu.au.
Jazyk:	angličtina
Zdroj:	Journal of clinical immunology [J Clin Immunol] 2023 Nov; Vol. 43 (8), pp. 1706-1723. Date of Electronic Publication: 2023 Jul 05.
DOI:	10.1007/s10875-023-01540-5
Abstrakt:	Although a more efficient adaptive humoral immune response has been proposed to underlie the usually favorable outcome of pediatric COVID-19, the breadth of viral and vaccine cross-reactivity toward the ever-mutating Spike protein among variants of concern (VOCs) has not yet been compared between children and adults. We assessed antibodies to conformational Spike in COVID-19-naïve children and adults vaccinated by BNT162b2 and ChAdOx1, and naturally infected with SARS-CoV-2 Early Clade, Delta, and Omicron. Sera were analyzed against Spike including naturally occurring VOCs Alpha, Beta, Gamma, Delta, and Omicron BA.1, BA.2, BA.5, BQ.1.1, BA2.75.2, and XBB.1, and variants of interest Epsilon, Kappa, Eta, D.2, and artificial mutant Spikes. There was no notable difference between breadth and longevity of antibody against VOCs in children and adults. Vaccinated individuals displayed similar immunoreactivity profiles across variants compared with naturally infected individuals. Delta-infected patients had an enhanced cross-reactivity toward Delta and earlier VOCs compared to patients infected by Early Clade SARS-CoV-2. Although Omicron BA.1, BA.2, BA.5, BQ.1.1, BA2.75.2, and XBB.1 antibody titers were generated after Omicron infection, cross-reactive binding against Omicron subvariants was reduced across all infection, immunization, and age groups. Some mutations, such as 498R and 501Y, epistatically combined to enhance cross-reactive binding, but could not fully compensate for antibody-evasive mutations within the Omicron subvariants tested. Our results reveal important molecular features central to the generation of high antibody titers and broad immunoreactivity that should be considered in future vaccine design and global serosurveillance in the context of limited vaccine boosters available to the pediatric population. (© 2023. The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink